Summary: The main rationale underlying this study is that prostate cancer clinical trials are lacking representation from racial and ethnic minority groups. St...
Summary: To learn if ivonescimab can help to control advanced cSCC. The safety and effects of ivonescimab will also be studied....
Summary: The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or meta...
Summary: This prospective, interventional, open-label, phase 3 randomized study evaluates a multimodal analgesia discharge pathway to reduce automatic opioid p...
Summary: The purpose of this study is to understand the safety and estimate the efficacy of anti-CD3 x anti-HER2 bispecific antibody (HER2Bi) armed fresh perip...
Summary: This clinical trial tests how well a point of prostate cancer diagnosis (PPCD) virtual reality assistant (ViRA) intervention works in supporting Black...
Summary: The researchers are doing this study to test the capabilities of a new total-body PET scanner called the Biograph Vision Quadra. The researchers want ...
Summary: The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer....
Summary: The purpose of this study is to see whether giving a lower (de-escalated) dose of radiation therapy to some parts of the prostate can reduce side effe...
Summary: Many patients may face long-term urinary side effects following stereotactic body radiation therapy (SBRT), including increased urinary frequency, dys...
Saruparib is a new pill that blocks PARP1, a protein cancer cells use to repair DNA. Laboratory and early‑phase studies indicated 60 mg once a day as the recommended dose. Adding saruparib might hold the cancer in check for longer.
VISIT
This global Phase 3 study is designed to investigate and confirm the benefits and risks associated with TLX591 administered together with standard of care (SoC), as compared to the best SoC alone. The study is being conducted in patients with metastatic…
VISIT
XALute is a research study for men with advanced prostate cancer (cancer has spread to other parts of the body) who have already been treated with chemotherapy.
VISIT
The primary objective of this clinical trial is to assess the effcacy of combining the study medicine (mevrometostat) with a standard therapy (enzalutamide) to treat metastatic castration-resistant prostate cancer (mCRPC) compared to placebo in combination with enzalutamide.
VISIT
The primary goal of this clinical trial is to determine if adding mevrometostat to the standard therapy (enzalutamide) is more effective in treating metastatic castration-sensitive prostate cancer compared to enzalutamide alone with a placebo.
VISIT
The Omaha-003 clinical trial is for participants who have metastatic castration-resistant prostate cancer that failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.
VISIT
The Omaha-004 clinical trial is for participants who have metastatic castration-resistant prostate cancer that failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer.
VISIT
The goal of substudy 01A is to evaluate the safety and efficacy of opevesostat-based treatment combinations, or as a single agent, in participants with mCRPC.
VISITResearchers seek to learn how safe I-DXd is, by itself or with other drugs, identify the best dose, and see how the cancer responds to treatment for people with metastatic castration resistant prostate cancer (mCRPC)
VISIT
Researchers seek to learn how safe I-DXd is and see how well it works compared to docetaxel, which is a standard treatment for mCRPC.
VISIT
The purpose of this study is to evaluate whether Saruparib (AZD5305) is superior to placebo when added to standard radiation therapy (RT) and androgen deprivation therapy (ADT). The primary measure of effectiveness will be metastasis-free survival in participants with high-risk…
VISIT
